• Users Online: 222
  • Print this page
  • Email this page
Year : 2018  |  Volume : 1  |  Issue : 4  |  Page : 142-144

Development of drug-induced arthritis in a glioblastoma patient treated with pembrolizumab

Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA

Correspondence Address:
Dr. Katherine B Peters
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, PO Box 3624, Durham, NC 27710
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/glioma.glioma_28_18

Rights and Permissions

Glioblastoma (GBM, WHO Grade IV) is the most aggressive form of primary brain cancer in adults, and as with other cancers, clinical investigations to use immunotherapy as a possible therapeutic option for GBM are underway. One form of immunotherapy is immune checkpoint inhibition that targets the programmed cell death-1 (PD-1) receptor on lymphocytes. While PD-1 receptor inhibitors, such as pembrolizumab, are often tolerable, there can be dose-limiting immune-related adverse effects, which have the potential to result in impaired health-related quality of life. This case report discusses one patient with recurrent GBM who received pembrolizumab and developed refractory drug-induced arthritis.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded291    
    Comments [Add]    

Recommend this journal